Evolutionary Genomics, Inc. Stock
Stocks
FNAM
US30051F1012
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000200 USD | -.--% |
|
-.--% | - |
| 23-03-09 | Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 23-03-08 | Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 2.99M 2.6M 2.42M 2.22M 4.2M 286M 4.27M 28.56M 11.21M 142M 11.25M 11M 477M | P/E 2021 |
-1.34x | P/E 2022 | -2x |
|---|---|---|---|---|---|
| Enterprise Value | 6.16M 5.36M 4.99M 4.58M 8.64M 588M 8.78M 58.77M 23.06M 293M 23.14M 22.63M 982M | EV / Sales 2021 |
-
| EV / Sales 2022 | - |
| Free-Float |
67.35% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 year | 0 | 0 | |
| 3 years | 0 | 0 | |
| 5 years | 0 | 1.05 | |
| 10 years | 0 | 5.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Walter Messier
CTO | Chief Tech/Sci/R&D Officer | 71 | 1999-12-31 |
Steve Warnecke
CEO | Chief Executive Officer | 70 | 2014-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Steve Warnecke
CHM | Chairman | 70 | 2014-09-30 |
| Director/Board Member | 76 | 1999-12-31 | |
Mark Boggess
BRD | Director/Board Member | 66 | 2009-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 5/23/22 | Fiscal year | Chief Executive Officer | 185,715 | 2.8074% | ||
| 5/23/22 | Fiscal year | Founder | 278,571 | 4.2111% | ||
| 5/23/22 | Fiscal year | Founder | 55,714 | 0.8422% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -.--% | -99.96% | 1.33K | ||
| -1.40% | +2.59% | -1.71% | +11.28% | 48.53B | ||
| -2.41% | -0.90% | +403.17% | +614.40% | 39.87B | ||
| -1.16% | +12.96% | +26.45% | +5.03% | 38.68B | ||
| -1.88% | -3.03% | +4.94% | +47.52% | 35.13B | ||
| -1.74% | +5.12% | +9.58% | +46.02% | 29.79B | ||
| -2.85% | -3.92% | - | - | 16.08B | ||
| -0.21% | -4.04% | +35.09% | +127.95% | 16.11B | ||
| -0.64% | +2.65% | +1.25% | +8.92% | 13.61B | ||
| -1.19% | -1.32% | -3.32% | -34.94% | 12.62B | ||
| Average | -1.35% | +0.87% | +52.83% | +80.69% | 25.04B | |
| Weighted average by Cap. | -1.60% | +1.99% | +76.87% | +128.10% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | - | - |
| Net income | -2.79M -2.43M -2.26M -2.08M -3.92M -267M -3.98M -26.65M -10.46M -133M -10.49M -10.26M -445M | -1.93M -1.68M -1.57M -1.44M -2.71M -185M -2.76M -18.45M -7.24M -91.96M -7.27M -7.11M -308M |
| Net Debt | 3.53M 3.07M 2.86M 2.62M 4.95M 337M 5.03M 33.67M 13.21M 168M 13.26M 12.97M 562M | 3.17M 2.75M 2.56M 2.35M 4.44M 302M 4.51M 30.2M 11.85M 150M 11.89M 11.63M 505M |
Employees
3
- Stock Market
- Stocks
- FNAM Stock
Select your edition
All financial news and data tailored to specific country editions
















